Oncology
ASH 2025
At the 67th American Society of Hematology Annual Meeting and Exhibition this weekend, we will be sharing our latest innovations in blood cancer research and development.
Investors
We announced our quarter 3 2025 results on Wednesday, October 29th.
Press releases
- GSK’227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA
- GSK data at ASH show potential to redefine outcomes for people living with blood cancers
- TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc.

GSK Global links
Visit our Global site for additional features








